|
Post by gareaudan on Aug 12, 2018 9:49:54 GMT -5
One analyst that I remember called Afrezza a niche drug. I believe it is a niche drug for T2's in the United States. I was diagnosed T2 about 15 years ago. I have posted my reasons for believing that and it is based on discussions with my endo. I believe the real market is T1's and more specifically juvenile T1's. Young people embrace technology and they would most likely figure out titration more quickly than adults. Using a CGM and Afrezza is clearly a winning combination.
SNY said that Afrezza is not commercially viable in the USA. They threw in the towel 6 months after they started selling Afrezza. They went in another direction. Is it that Afrezza really isn't commercially viable or was that their excuse to legally exit the partnership agreement? Afrezza is not yet commercially viable in the USA. Will it be? I hold out hope, but I don't see it happening by targeting T2's. We are working towards approval for juvenile use. In order to achieve success MNKD will have to get doctors to prescribe Afrezza for young patients. Will they do that? That is the multi million dollar question. The company is not dead. Mike has done a good job so far and if financing is worked out I think we will eventually see daylight and profitability.
i believe that they precised "with the current labeling" which already has been change since then.
|
|
|
Post by tomtabb on Aug 12, 2018 11:01:51 GMT -5
What bothers me is if you google afrezza for news and just for the past month, what you immediately see:
"MannKind: Afrezza Is Worthless"
"MannKind - Afrezza Scripts Dip As Cash Crunch Continues"
"MannKind - Afrezza Scripts Recover From Holiday Dip"
If you do the same for fiasp:
"Back to Fiasp | Diabettech - Diabetes and Technology"
"FIASP and Omnipod... Someone? - Insulin - TuDiabetes Forum"
"Novo Nordisk Korea gets nod for diabetes drug Fiasp"
And do the same for ultra-rapid insulin:
"The Ultra-rapid Insulin (URI) BioChaperone Lispro (BCLIS ... - Diabetes"
"...of Ultra-rapid Insulin BioChaperone Lispro (BCLIS) - Diabetes"
"...The Ultra-rapid Insulin (URI) BioChaperone Lispro ... - ResearchGate"
What's wrong with this picture?
|
|
|
Post by nylefty on Aug 12, 2018 11:19:18 GMT -5
One analyst that I remember called Afrezza a niche drug. I believe it is a niche drug for T2's in the United States. I was diagnosed T2 about 15 years ago. I have posted my reasons for believing that and it is based on discussions with my endo. I believe the real market is T1's and more specifically juvenile T1's. Young people embrace technology and they would most likely figure out titration more quickly than adults. Using a CGM and Afrezza is clearly a winning combination. Those young people will also help their parents, uncles, aunts, and grandparents figure out how to use Afrezza, just as they taught them how to use smartphones and other technology.
|
|
|
Post by harryx1 on Aug 12, 2018 12:37:23 GMT -5
One analyst that I remember called Afrezza a niche drug. I believe it is a niche drug for T2's in the United States. I was diagnosed T2 about 15 years ago. I have posted my reasons for believing that and it is based on discussions with my endo. I believe the real market is T1's and more specifically juvenile T1's. Young people embrace technology and they would most likely figure out titration more quickly than adults. Using a CGM and Afrezza is clearly a winning combination.
SNY said that Afrezza is not commercially viable in the USA. They threw in the towel 6 months after they started selling Afrezza. They went in another direction. Is it that Afrezza really isn't commercially viable or was that their excuse to legally exit the partnership agreement? Afrezza is not yet commercially viable in the USA. Will it be? I hold out hope, but I don't see it happening by targeting T2's. We are working towards approval for juvenile use. In order to achieve success MNKD will have to get doctors to prescribe Afrezza for young patients. Will they do that? That is the multi million dollar question. The company is not dead. Mike has done a good job so far and if financing is worked out I think we will eventually see daylight and profitability.
nadathing read my article Mannkind: Afrezza Is Far From Worthless especially the Type 2 Diabetes section and then let me know if you think Afrezza is/will be just a niche drug for that patient population.
|
|
|
Post by steve on Aug 12, 2018 13:10:22 GMT -5
Ok I am posting here for the sanity of everyone. I suspect I will get kicked out since this is a cheerleader board as it is but so what- Here's my honest opinion - you can take it or leave it- I was with Mannkind when Al Mann was alive and when Sanofi signed a deal with them. I got suckered into to buying the stock at $6, 7,8, 9 and $10 (before the famous Matt P reverse 1-5 split. I also bought at 5, 4, 3, 2, 1, 64 cents and back at $1, 2, 3 back down to $2. I got so tired I sold it all at $2- In other words, I lost a bunch of money in this stock (a big bunch). I spoke to Sanofi several times when they were partners, relayed a bunch of info to Matt P, spoke to him countless times as well all Mike C and others. One thing the Sanofi guy (he was their head of Afrezza sales) told me - stuck with me- nice niche product, hopefully, it will sell. I didn't believe him. I had my rose-colored eye glasses on -- and continued to have them for another two-three years Guess I was wrong- I admit it. Cut your loses. Move on. This company is dead. Just my advice. Yet another rising skeptic id. lol Tell ya what. I'll buy more.
|
|
|
Post by peppy on Aug 12, 2018 13:27:59 GMT -5
What bothers me is if you google afrezza for news and just for the past month, what you immediately see: "MannKind: Afrezza Is Worthless" "MannKind - Afrezza Scripts Dip As Cash Crunch Continues" "MannKind - Afrezza Scripts Recover From Holiday Dip" If you do the same for fiasp: "Back to Fiasp | Diabettech - Diabetes and Technology" "FIASP and Omnipod... Someone? - Insulin - TuDiabetes Forum" "Novo Nordisk Korea gets nod for diabetes drug Fiasp" And do the same for ultra-rapid insulin: "The Ultra-rapid Insulin (URI) BioChaperone Lispro (BCLIS ... - Diabetes" "...of Ultra-rapid Insulin BioChaperone Lispro (BCLIS) - Diabetes" "...The Ultra-rapid Insulin (URI) BioChaperone Lispro ... - ResearchGate" What's wrong with this picture? Lies, is what is wrong with the picture? Looks like paid for lies? Regarding the thread title, "product not selling, face it": People are not allowed the make their own choices regarding insulin, Afrezza or the subq rapid acting insulins. The choices are made for people based on insurance coverage. We are not selling iPhones.
|
|
|
Post by MnkdWASmyRtrmntPlan on Aug 12, 2018 14:59:11 GMT -5
Admins, please delete this thread and Rising Skeptic's "reality" account.
|
|
|
Post by MnkdWASmyRtrmntPlan on Aug 12, 2018 15:08:02 GMT -5
One analyst that I remember called Afrezza a niche drug. I believe it is a niche drug for T2's in the United States. I was diagnosed T2 about 15 years ago. I have posted my reasons for believing that and it is based on discussions with my endo. I believe the real market is T1's and more specifically juvenile T1's. Young people embrace technology and they would most likely figure out titration more quickly than adults. Using a CGM and Afrezza is clearly a winning combination.
SNY said that Afrezza is not commercially viable in the USA. They threw in the towel 6 months after they started selling Afrezza. They went in another direction. Is it that Afrezza really isn't commercially viable or was that their excuse to legally exit the partnership agreement? Afrezza is not yet commercially viable in the USA. Will it be? I hold out hope, but I don't see it happening by targeting T2's. We are working towards approval for juvenile use. In order to achieve success MNKD will have to get doctors to prescribe Afrezza for young patients. Will they do that? That is the multi million dollar question. The company is not dead. Mike has done a good job so far and if financing is worked out I think we will eventually see daylight and profitability.
nadathing read my article Mannkind: Afrezza Is Far From Worthless especially the Type 2 Diabetes section and then let me know if you think Afrezza is/will be just a niche drug for that patient population. Harry, that's a great article. I assume you posted it on Proboards in the past, but I missed it. Have you tried getting it posted to Seeking Alpha?
|
|
|
Post by mnkdfann on Aug 12, 2018 15:32:40 GMT -5
Admins, please delete this thread and Rising Skeptic's "reality" account. 'Reality' registered back in 2015, many months before you did. If he/she is RS, then that was quite a long con. I've been here longer than both of you. Though I know I am still a newbie in the eyes of many.
|
|
|
Post by harryx1 on Aug 12, 2018 17:15:49 GMT -5
Harry, that's a great article. I assume you posted it on Proboards in the past, but I missed it. Have you tried getting it posted to Seeking Alpha? MnkdWASmyRtrmntPlan - I tried numerous times to get seeking alpha to publish it but the wouldn't accept it. Yes I posted it here earlier this week.
|
|
|
Post by MnkdWASmyRtrmntPlan on Aug 12, 2018 17:22:52 GMT -5
Admins, please delete this thread and Rising Skeptic's "reality" account. 'Reality' registered back in 2015, many months before you did. If he/she is RS, then that was quite a long con. I've been here longer than both of you. Though I know I am still a newbie in the eyes of many. Ah, you are right, mnkdfann. I posted that from my cell and couldn't do that research. So, I read through his posts and see that he probably is a legitimate investor. Sorry, reality. The writing style and the moniker "reality" just really seemed to be written by RS or someone from the MNKD-Con darkside. So, if your story is truly legitimate, then I understand your feelings. I and most others are still in this board are still in the same boat that you were in. Most of us here, however, have a completely different opinion of the future of MNKD. 5 years is a long time to continue to lose money in a stock. You sold at $2.00, and we still hold, so right now, you are "slightly" better off than the rest of us. If we continue to leave our money in, the "reality" MAY actually be that it may be another 5 years before we even break even again. However, I do not think that will be the case, and nor do I believe that the majority on this board think that way. We believe that the "reality" will be positive much sooner than that, and it will eventually be a "some-large-number-here"-bagger that will be very rewarding to those of us with patience (and to our heirs). Sales have not been what we have all wanted to see, but there is so much opportunity for great things to come to MNKD. Mike C. and the great team that he has assembled have set the table. Sure, any day now, a great partner may be introduced that would be the white night investor or complementary partner (heavy in cash and short on a good future plan) that we have all been dreaming of. But, with or without that, I believe that MNKD will survive and eventually thrive ... and in the end, us true longs will have to live with an embarrassment of riches. At that point, my rosy glasses will turn green. So, we may be a bunch of dreamers, and that is not an especially wise investment strategy, but we also might be the savviest investors that have just had an incredibly long streak of bad luck. But, we are still in the game, so we will benefit if and when MNKD SP hits the hockey-stick inflection point, and you will not. You will have just lost a lot of money and bailed. I (and probably most others on this board) believe this is more likely the best time to buy MNKD stock than to sell it. In an altruistic way, many of us are also disciples of Al, and we want to see his vision and all of his brilliant work become reality and become so helpful to Mankind. And in a personal way, many of us or our children are diabetic, or will become so in the future, so we also want to see Afrezza become the standard of care for that time. So, when you make statements that everyone should just sell now, well, you can imagine that that does annoy us. If you really are just an investor, my imagination fails me when I wonder why you chose the name "reality" when you joined that long ago. Another thing I really can't understand is that you have been on this board for so long, so you should know that MNKD.Proboards is for folk who are Pro-MNKD. I can't understand why you even came back on this board and posted that. You said something to the effect that you knew it would not be well-received and you were correct. Anyway, Best of luck to you.
|
|
|
Post by mytakeonit on Aug 12, 2018 17:43:06 GMT -5
5 years? ... Nate and I will be here for "decades" !!! If I live that long ...
|
|
|
Post by uvula on Aug 12, 2018 17:50:03 GMT -5
I share "reality"'s frustration but came to a different conclusion. I figure that since I already lost 95% of my investment it makes no sense to sell my shares now. I know that Afrezza works. I know that Kendall would not have accepted the job if there was no chance of the company being successful. If I sell my shares now and the share price recovers I will hate myself more than if I hold my shares and they become worthless. So I keep holding my shares. Not exactly a ringing endorsement of the company but I haven't given up hope. (I might buy more shares AFTER MNKD raises enough money to extend the runway for a year.)
|
|
|
Post by kimi on Aug 12, 2018 17:50:33 GMT -5
Altruismus ist nur eine gerissenere Form des Egoismus, getreu dem Motto: "Kratze einen Altruisten und du siehst einen Heuchler bluten!
feel free to translate, I can't.
|
|
|
Post by nadathing on Aug 12, 2018 18:20:43 GMT -5
Harry: Great article but it does not change my opinion. I have been T2 for over 15 years. I see an endo at The International Diabetes Center in St. Louis Park (Minneapolis) MN. My endo told me they will not prescribe insulin to a T2 until their pancreas is no longer producing insulin. I understand and acknowledge that many T2's are not within range using current treatments. I believe Afrezza would be extremely valuable to the T2 population. What I don't believe is that it is going to happen any time soon. Endos are resistant to change old habits and how they treat T2's. They are stuck on diet, exercise and oral meds following diagnosis. If that doesn't work they move to other drugs, including GLP-1's. I have been using Trulicity for about three years and prior to that I was on Bydureon for 4+ years which included a 3 year P3 trial. I know the risk associated with using a GLP-1. So does my endo. My last A1c was 5.8. I can't imagine an endo changing a regiment if a T2 is in range.
I am not arguing the value of Afrezza in treating T2's. I am just suggesting that this is a battle to change old habits in the medical community and I do not see that happening in the near future. It is an uphill battle and IMO will take many, many years to change. Will it happen? Probably, but I am not banking on making a profit on MNKD from the T2 market.
|
|